Urogen Pharma Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. We will continue with the next session. Hi, everyone. I'm Paul Choi, SMid Cap Biotechnology Analyst here at Goldman Sachs. And thank you for joining us for our 42nd Annual Global Healthcare Conference.
Our next session will be with UroGen, and we're pleased to have CEO, Liz Barrett; and Jeff Bova, Head of Commercial, joining us here. What we'll do is turn it over to Liz for some opening comments and then go into Q&A. As with prior sessions, if investors have questions along the way, please feel free to submit them via the webcast portal. Alternatively, you can e-mail them to me, and I'll read them out loud time permitting.
And with that, I'll turn it over to Liz.
Thanks, Paul, and thanks for having us. I asked Jeff to join because I know a lot of the interest is around what's happening with the commercial launch. It's an exciting time for UroGen.
I always say that I say this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
